JP2021529524A5 - - Google Patents

Info

Publication number
JP2021529524A5
JP2021529524A5 JP2020573044A JP2020573044A JP2021529524A5 JP 2021529524 A5 JP2021529524 A5 JP 2021529524A5 JP 2020573044 A JP2020573044 A JP 2020573044A JP 2020573044 A JP2020573044 A JP 2020573044A JP 2021529524 A5 JP2021529524 A5 JP 2021529524A5
Authority
JP
Japan
Prior art keywords
seq
antigen
binding fragment
glyco
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020573044A
Other languages
English (en)
Japanese (ja)
Other versions
JP7541930B2 (ja
JP2021529524A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/039883 external-priority patent/WO2020006449A1/en
Publication of JP2021529524A publication Critical patent/JP2021529524A/ja
Publication of JP2021529524A5 publication Critical patent/JP2021529524A5/ja
Application granted granted Critical
Publication of JP7541930B2 publication Critical patent/JP7541930B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020573044A 2018-06-29 2019-06-28 抗グリコmuc1抗体およびその使用 Active JP7541930B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862691887P 2018-06-29 2018-06-29
US62/691,887 2018-06-29
US201962802865P 2019-02-08 2019-02-08
US62/802,865 2019-02-08
PCT/US2019/039883 WO2020006449A1 (en) 2018-06-29 2019-06-28 Anti-glyc0-muc1 antibodies and their uses

Publications (3)

Publication Number Publication Date
JP2021529524A JP2021529524A (ja) 2021-11-04
JP2021529524A5 true JP2021529524A5 (https=) 2022-07-06
JP7541930B2 JP7541930B2 (ja) 2024-08-29

Family

ID=68987626

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020573044A Active JP7541930B2 (ja) 2018-06-29 2019-06-28 抗グリコmuc1抗体およびその使用

Country Status (5)

Country Link
US (2) US12269892B2 (https=)
EP (1) EP3814384A4 (https=)
JP (1) JP7541930B2 (https=)
CN (1) CN112996816B (https=)
WO (1) WO2020006449A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023516080A (ja) * 2020-03-06 2023-04-17 ジーオー セラピューティクス,インコーポレイテッド 抗グリコcd44抗体およびその使用
US11970546B2 (en) * 2020-07-31 2024-04-30 R.P. Scherer Technologies, Llc Antibody specific for Mucin-1 and methods of use thereof
WO2023121448A1 (en) * 2021-12-21 2023-06-29 Merus N.V. Binding domains against cancer-associated muc1
WO2025114381A1 (en) * 2023-11-27 2025-06-05 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Muc1 antibodies and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68922806T2 (de) 1988-03-11 1996-02-29 Biomembrane Inst Monoklonale antikörper und herstellung eines impfstoffes gegen menschliche krebsantigene durch immunisierung mit menschlichem und tierischem mucin und mit synthetischen gluciden-trägerkonjugaten.
US7147850B2 (en) 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
WO2001075110A2 (en) 2000-03-30 2001-10-11 Dyax Corp. Mucin-1 specific binding members and methods of use thereof
US7338932B2 (en) 2000-05-11 2008-03-04 Glycozym Aps Methods of modulating functions of polypeptide GalNAc-transferases and of screening test substances to find agents herefor, pharmaceutical compositions comprising such agents and the use of such agents for preparing medicaments
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
CN1141142C (zh) * 2001-02-08 2004-03-10 北京迪威华宇生物技术有限公司 人乳腺癌muc-1抗原基因工程疫苗
DE10303664A1 (de) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
AU2007304590A1 (en) 2006-10-04 2008-04-10 Cancer Research Technology Limited Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies
ES2593484T3 (es) 2007-03-29 2016-12-09 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
EP2014302A1 (en) 2007-07-12 2009-01-14 Institut Curie An antibody specific for the Tn antigen for the treatment of cancer
CA2694542C (en) * 2007-07-31 2017-08-29 Otsuka Chemical Co., Ltd. Method for producing peptide
JP5532401B2 (ja) 2007-12-05 2014-06-25 協和発酵キリン株式会社 ヘパリン結合上皮細胞増殖因子様増殖因子に結合するモノクローナル抗体
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
CN102264765B (zh) 2008-10-28 2016-01-20 盐野义制药株式会社 抗muc1抗体
PE20120540A1 (es) 2009-05-27 2012-05-09 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
US9588121B2 (en) * 2009-11-06 2017-03-07 Go Therapeutics, Inc. Method for early detection of cancer
JP5660486B2 (ja) 2010-02-12 2015-01-28 国立大学法人 鹿児島大学 ムチン1(muc1)タンパク質に対する抗体及びその用途
WO2011135869A1 (ja) 2010-04-28 2011-11-03 塩野義製薬株式会社 新規なmuc1抗体
EP2407487A1 (en) * 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
MX2014014162A (es) 2012-05-24 2015-02-04 Hoffmann La Roche Anticuerpos multiespecificos.
CN104379169A (zh) 2012-08-14 2015-02-25 Ibc药品公司 用于治疗疾病的t-细胞重定向双特异性抗体
HUE042040T2 (hu) 2012-09-27 2019-06-28 Merus Nv Bispecifikus IGG antitestek mint T-sejt kapcsolók
WO2014163684A1 (en) * 2013-04-03 2014-10-09 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
WO2015120180A1 (en) 2014-02-05 2015-08-13 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variants
US10239950B2 (en) * 2014-04-28 2019-03-26 Medicinal Chemistry Pharmaceuticals, Co., Ltd. Anti-MUC1 antibody or antigen-binding fragment thereof and uses thereof
EP3150636A1 (en) 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalent multispecific antibodies
CN108290958B (zh) 2015-10-02 2021-12-28 豪夫迈·罗氏有限公司 多特异性抗体
WO2018178047A1 (en) 2017-03-29 2018-10-04 Glycotope Gmbh Multispecific antibody constructs binding to muc1 and cd3

Similar Documents

Publication Publication Date Title
JP7562528B2 (ja) 抗体及びその用途
JP7620807B2 (ja) 抗SIRPα抗体およびその適用
JP2022512132A5 (https=)
JP2020073504A5 (https=)
JP2019116474A5 (https=)
JP2021510710A5 (https=)
KR20210100654A (ko) Cd3 항체 및 그의 약제학적 용도
JP2019527553A5 (https=)
JP2020508655A5 (https=)
JP2024001073A5 (https=)
JP2021529524A5 (https=)
JP2023540526A5 (https=)
JP2018522888A5 (https=)
AU2019242559A1 (en) Monoclonal antibodies that bind to SSEA4 and uses thereof
CN113150156B (zh) 抗tigit抗体及其用途
JP2021512604A5 (https=)
JP2024515560A5 (https=)
WO2023071676A1 (zh) 一种抗her2/抗pd-l1双功能抗体及其应用
CN119213023A (zh) Ilt3和cd3结合剂以及其使用方法
CA3229160A1 (en) Bispecific tetravalent antibody targeting egfr and her3
US12577314B2 (en) Anti-BCMA/anti-4-1BB bispecific antibodies and uses thereof
JP2024531915A5 (https=)
KR20250012612A (ko) 고형 종양을 치료하는 방법
JP2024543828A5 (https=)
JP2024512324A5 (https=)